Guilin Sanjin Pharmaceutical Co Ltd (002275) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guilin Sanjin Pharmaceutical Co Ltd (002275) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥117.62 Million ≈ $17.21 Million USD) by net assets (CN¥3.24 Billion ≈ $474.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check strategic asset allocation of Guilin Sanjin Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.
Guilin Sanjin Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Guilin Sanjin Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. See net assets of Guilin Sanjin Pharmaceutical Co Ltd for net asset value and shareholders' equity analysis.
Guilin Sanjin Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guilin Sanjin Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Aladdin Biochemical Technology Co. Ltd. A
SHG:688179
|
N/A |
|
Orezone Gold Corporation
AU:ORE
|
0.249x |
|
Trican Well Service Ltd.
TO:TCW
|
0.127x |
|
Hapvida Participações e Investimentos S.A.
SA:HAPV3
|
-0.014x |
|
Shunfa Hengye Corp
SHE:000631
|
0.000x |
|
Topscore Fashion
SHG:603608
|
0.016x |
|
Rackspace Technology Inc
NASDAQ:RXT
|
-0.004x |
|
Xiamen East Asia Machinery Industrial Co. Ltd.
SHE:301028
|
N/A |
Annual Cash Flow Conversion Efficiency for Guilin Sanjin Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual cash flow conversion efficiency of Guilin Sanjin Pharmaceutical Co Ltd from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see 002275 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.01 Billion ≈ $440.42 Million |
CN¥588.33 Million ≈ $86.09 Million |
0.195x | +0.25% |
| 2023-12-31 | CN¥2.82 Billion ≈ $412.21 Million |
CN¥549.25 Million ≈ $80.37 Million |
0.195x | +3.76% |
| 2022-12-31 | CN¥2.81 Billion ≈ $411.68 Million |
CN¥528.67 Million ≈ $77.36 Million |
0.188x | +30.08% |
| 2021-12-31 | CN¥2.84 Billion ≈ $415.55 Million |
CN¥410.24 Million ≈ $60.03 Million |
0.144x | -28.52% |
| 2020-12-31 | CN¥2.96 Billion ≈ $433.00 Million |
CN¥597.99 Million ≈ $87.50 Million |
0.202x | +21.50% |
| 2019-12-31 | CN¥2.82 Billion ≈ $411.99 Million |
CN¥468.29 Million ≈ $68.52 Million |
0.166x | -15.39% |
| 2018-12-31 | CN¥2.81 Billion ≈ $410.70 Million |
CN¥551.73 Million ≈ $80.73 Million |
0.197x | +34.52% |
| 2017-12-31 | CN¥2.65 Billion ≈ $388.35 Million |
CN¥387.82 Million ≈ $56.75 Million |
0.146x | -33.97% |
| 2016-12-31 | CN¥2.43 Billion ≈ $354.94 Million |
CN¥536.85 Million ≈ $78.56 Million |
0.221x | +30.14% |
| 2015-12-31 | CN¥2.34 Billion ≈ $342.87 Million |
CN¥398.50 Million ≈ $58.31 Million |
0.170x | -0.47% |
| 2014-12-31 | CN¥2.32 Billion ≈ $339.57 Million |
CN¥396.53 Million ≈ $58.02 Million |
0.171x | +19.83% |
| 2013-12-31 | CN¥2.20 Billion ≈ $322.38 Million |
CN¥314.16 Million ≈ $45.97 Million |
0.143x | -2.08% |
| 2012-12-31 | CN¥2.08 Billion ≈ $304.06 Million |
CN¥302.59 Million ≈ $44.28 Million |
0.146x | -15.34% |
| 2011-12-31 | CN¥1.98 Billion ≈ $290.15 Million |
CN¥341.05 Million ≈ $49.91 Million |
0.172x | +8.44% |
| 2010-12-31 | CN¥1.80 Billion ≈ $263.37 Million |
CN¥285.49 Million ≈ $41.78 Million |
0.159x | -22.16% |
| 2009-12-31 | CN¥1.78 Billion ≈ $260.89 Million |
CN¥363.29 Million ≈ $53.16 Million |
0.204x | -16.01% |
| 2008-12-31 | CN¥787.10 Million ≈ $115.18 Million |
CN¥190.97 Million ≈ $27.94 Million |
0.243x | +7.63% |
| 2007-12-31 | CN¥729.25 Million ≈ $106.71 Million |
CN¥164.39 Million ≈ $24.06 Million |
0.225x | -35.03% |
| 2006-12-31 | CN¥627.33 Million ≈ $91.80 Million |
CN¥217.67 Million ≈ $31.85 Million |
0.347x | -- |
About Guilin Sanjin Pharmaceutical Co Ltd
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China and internationally. The company offers three gold particles, Guilin watermelon frost, watermelon frost lozenges, throat clearing spray, Naomaitai capsules, vertigo tablets, Xuanyunning granules, Gejie dingchuan capsule, compound panax notoginseng stomachache … Read more